doi:10.1007/s13669-020-00302-z
The medical advice for people at this point is tentative
The study concluded that while PR-104 demonstrated biological proof-of-principle for targeting hypoxia and metabolic vulnerabilities in leukemia, its clinical use is constrained by toxicity, supporting the need for biomarker-guided selection and combination approaches rather than monotherapy (281)
Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo V, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M
DOI.org (Crossref) , Sports Medicine (Auckland, N.Z.) , vol